La FDA aprueba Afrezza para pacientes pediátricos con diabetes

29 de mayo de 2026

Reportado por IA

La FDA de EE. UU. ha aprobado Afrezza para niños y adolescentes con diabetes de 6 años en adelante. MannKind Corporation llevó a cabo una conferencia telefónica el 29 de mayo de 2026 para discutir la decisión.

MannKind Corporation anunció la aprobación durante una llamada dirigida por el director ejecutivo Michael Castagna. Él describió el día como un momento histórico para la empresa, la comunidad diabética y los pacientes jóvenes. Castagna señaló que el fundador Al Mann había imaginado durante mucho tiempo que el tratamiento llegaría a los niños, y la empresa está cumpliendo con ese objetivo.

Fluvoxamine eases severe fatigue in long COVID patients

31 de marzo de 2026 Reportado por IA Imagen generada por IA

A study shows the antidepressant fluvoxamine reduces severe fatigue in long COVID patients. In a randomized trial of 399 adults, it was compared with metformin and placebo. Physician Judith Bruchfeld describes the findings as interesting.

Oral GLP-1 pill shows strong results in diabetes trial

A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

1 de abril de 2026 Reportado por IA

The US Food and Drug Administration approved Foundayo, a new once-daily pill for obesity treatment, on Wednesday. Eli Lilly, the manufacturer, also produces the weight-loss injection Zepbound. The approval positions Foundayo as the second obesity pill cleared by the FDA.

Tecnología

14 de junio de 2026 20:53

La FDA aprueba Afrezza para pacientes pediátricos con diabetes

Artículos relacionados

Fluvoxamine eases severe fatigue in long COVID patients

Oral GLP-1 pill shows strong results in diabetes trial

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Dexcom outlines growth plans at 2026 investor day

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

France reimburses Mounjaro and Wegovy for severe obesity

Novo Nordisk heads to South African court over semaglutide copies

Three million kronor for research on mast cells in asthma

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Semaglutide shows strong weight loss results for adults over 65

Swedish team restores blood sugar control in diabetic mice

Innovative Cape Town clinic boosts outcomes for young kidney patients

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

FDA approves Travere Therapeutics' FILSPARI for FSGS

Study recommends treatment for all children with obesity

Este sitio web utiliza cookies